Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Needham analyst Gil Blum reiterates Celcuity (NASDAQ:CELC) with a Buy and maintains $70 price target.
Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, to...
Guggenheim analyst Brad Canino initiates coverage on Celcuity (NASDAQ:CELC) with a Buy rating and announces Price Target of ...
Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, to...
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Celcuity (NASDAQ:CELC) with a Buy and raises the price targ...
Needham analyst Gil Blum maintains Celcuity (NASDAQ:CELC) with a Buy and lowers the price target from $74 to $70.
Celcuity (NASDAQ:CELC) reported quarterly losses of $(0.93) per share which missed the analyst consensus estimate of $(0.88) by...
